Publication | Open Access

Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)

Cisplatin TherapyGastrointestinal OncologyMedicineTrastuzumab TherapyPathologyCancer TreatmentOncologyRadiation OncologyCancer ResearchHer2-positive Gastric Cancer